

## Research article

## Immunization of mice with YscF provides protection from *Yersinia pestis* infections

Jyl S Matson, Kelly A Durick, David S Bradley and Matthew L Nilles\*

Address: Department of Microbiology and Immunology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, USA

Email: Jyl S Matson - [matson@umich.edu](mailto:matson@umich.edu); Kelly A Durick - [kdurick@medicine.nodak.edu](mailto:kdurick@medicine.nodak.edu); David S Bradley - [dbradley@medicine.nodak.edu](mailto:dbradley@medicine.nodak.edu); Matthew L Nilles\* - [mnilles@medicine.nodak.edu](mailto:mnilles@medicine.nodak.edu)

\* Corresponding author

Published: 24 June 2005

Received: 26 March 2005

BMC Microbiology 2005, 5:38 doi:10.1186/1471-2180-5-38

Accepted: 24 June 2005

This article is available from: <http://www.biomedcentral.com/1471-2180/5/38>

© 2005 Matson et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** *Yersinia pestis*, the causative agent of plague, is a pathogen with a tremendous ability to cause harm and panic in populations. Due to the severity of plague and its potential for use as a bioweapon, better preventatives and therapeutics for plague are desirable. Subunit vaccines directed against the F1 capsular antigen and the V antigen (also known as LcrV) of *Y. pestis* are under development. However, these new vaccine formulations have some possible limitations. The F1 antigen is not required for full virulence of *Y. pestis* and LcrV has a demonstrated immunosuppressive effect. These limitations could dampen the ability of F1/LcrV based vaccines to protect against F1-minus *Y. pestis* strains and could lead to a high rate of undesired side effects in vaccinated populations. For these reasons, the use of other antigens in a plague vaccine formulation may be advantageous.

**Results:** Desired features in vaccine candidates would be antigens that are conserved, essential for virulence and accessible to circulating antibody. Several of the proteins required for the construction or function of the type III secretion system (TTSS) complex could be ideal contenders to meet the desired features of a vaccine candidate. Accordingly, the TTSS needle complex protein, YscF, was selected to investigate its potential as a protective antigen. In this study we describe the overexpression, purification and use of YscF as a protective antigen. YscF immunization triggers a robust antibody response to YscF and that antibody response is able to afford significant protection to immunized mice following challenge with *Y. pestis*. Additionally, evidence is presented that suggests antibody to YscF is likely not protective by blocking the activity of the TTSS.

**Conclusion:** In this study we investigated YscF, a surface-expressed protein of the *Yersinia pestis* type III secretion complex, as a protective antigen against experimental plague infection. Immunization of mice with YscF resulted in a high anti-YscF titer and provided protection against i.v. challenge with *Y. pestis*. This is the first report to our knowledge utilizing a conserved protein from the type III secretion complex of a gram-negative pathogen as a candidate for vaccine development.

## Background

*Yersinia pestis*, the causative agent of plague, causes rapidly progressing disease in humans with a high mortality rate, especially in the pneumonic form of the disease. Due to the severe nature of plague, its ability for aerosol transmission, and the potential for human to human transmission plague is considered to be a disease of high concern as an agent of biological warfare or biological terrorism [1]. For this reason, an improved vaccine for plague is desirable. Current efforts for vaccine development have focused on two proteins: LcrV (also known as the V antigen) and the capsular F1 antigen [2]. The best results to date have been obtained by using a combination of recombinant LcrV and F1 subunits [3] separately or as a fusion protein [4,5]. These subunit vaccines demonstrate very good protection against both pneumonic and systemic forms of plague [2] in mouse models. One of the potential limitations of these subunit vaccines is that F1 is not required for full virulence of *Y. pestis*, as F1-negative strains have the same LD<sub>50</sub> value as F1-positive strains [6-9]. A second limitation that could result in undesired side-effects in immunized individuals is the demonstrated immunosuppressive effect of LcrV [10-13]. Additionally, serologic diversity of LcrV has been reported, in *Yersinia* species other than *Y. pestis*, that could theoretically limit the usefulness of an LcrV based vaccine. While the recombinant subunit vaccines are very effective in experimental animals and offer protection against F1 minus strains of *Y. pestis* [2], the inclusion of other antigens with the LcrV/F1 subunit vaccine candidates could improve the ability of the resulting vaccine to offer protection against multiple *Y. pestis* strains, or the new antigens could be developed as separate vaccine candidates.

The type III secretion apparatus encoded on the low-calcium response (LCR) virulence plasmid, pCD1 in strain KIM [14], of *Y. pestis* is a conserved virulence mechanism that is absolutely required for virulence of *Y. pestis* [15]. YscF is a surface localized protein that is required both to secrete Yops and to translocate toxins into eukaryotic cells [16-19]. One report speculates that YscF polymerization is required for a YscF needle to puncture eukaryotic cell membranes [18]. Other researchers suggest that YscF and its homologs function to provide a base that a translocon complex is built upon, or that YscF builds a conduit from the bacterium to the eukaryotic membrane [20]. This suggestion seems more likely given that other proteins such as YopB, YopD, and LcrV are also required for translocation into eukaryotic cells [21-28]. Additionally, YscF needle producing *Y. enterocolitica* deficient in production of the translocators (LcrV, YopB, and YopD) do not translocate Yops into macrophages, demonstrating that the YscF-needle is not sufficient for translocation [19].


Most currently described pathogenesis-related type III secretion systems possess homologs to YscF. In pathogenic *Salmonella* and *Shigella*, the YscF homologs (PrgI and MxiH, respectively) have been demonstrated to form a needle structure that protrudes from the surface of bacterial cells [29-31]. The best-characterized homolog of YscF is EscF of enteropathogenic *E. coli* (EPEC). EscF is required for "attaching and effacing" (A/E) lesion formation on the intestinal mucosa and for type III secretion of effector proteins [32-34]. EscF is thought to be a structural component of the needle complex on the bacterial surface as it binds EspA, the major component of a filamentous surface organelle, and is required for formation of the EspA filaments. [32-34] However, this surface localization has never been visualized directly, as the only EscF antiserum generated was unable to recognize the native protein [33].

Based on the fact that YscF is thought to be a surface-expressed protein in *Y. pestis* and is required for virulence, we sought to determine if YscF could serve as a protective antigen against experimental plague infection. Immunization of mice with His-tagged YscF resulted in a high anti-YscF titer and significant protection against i.v. challenge with *Y. pestis*. The findings of this study suggest that YscF may be a potential plague vaccine candidate that could be used in conjunction with other plague antigens, or possibly alone if its efficacy can be improved by alternative delivery methods.

## Results and discussion

### Expression and purification of HT-YscF

To facilitate the purification of YscF, *yscF* was cloned into the overexpression plasmid pET24b (Novagen) to yield a hexahistidine-tag on the C-terminus of YscF (HT-YscF). *E. coli* BL21(DE3) harboring the HT-YscF expression plasmid, pJM119, was grown in one liter of LB broth [35] containing kanamycin at 37°C. Expression of HT-YscF was induced after 2 h of growth with 0.3 mM IPTG and then incubated until the A<sub>550</sub> reached ~1.0. Cells were harvested by centrifugation and disintegrated by passage through a French pressure cell at 20,000 lb/in<sup>2</sup>. Subsequent to disintegration, the extracts were clarified by centrifugation at 3,200 × g for 20 min at 4°C. Affinity purification of HT-YscF was performed using Talon resin (BD Clontech) using standard methods. Purity of the recovered protein (> 95 %) was estimated by SDS-PAGE on a 15% (wt/vol) gel followed by staining with a Coomassie blue stain. The purified HT-YscF ran as multiple bands on the gel, regardless of the presence or absence of a reducing agent, such as dithiothreitol (data not shown). A band that corresponded to the predicted size of HT-YscF was the dominant species and other larger bands could also be visualized (Figure 1A). Based on the sizes of these bands, it is likely that they represent dimers and other multimers of YscF. The presence of YscF multimers

**Figure 1**


Purified HT-YscF was run on SDS-PAGE gels (12.5% for Panels A and B, 15% Panel C) to analyze purity of the recovered protein. Panel A, separated proteins were stained with GelCode Blue stain (Pierce Chemical). Panel B, purified HT-YscF was immunoblotted to PVDF and probed with antibody specific for penta-histidine to identify which bands contained the His-tag. Panel C, purified HT-YscF was immunoblotted to PVDF and probed with post-immune serum from immunized mice.

is not surprising as YscF and its homologs are known to form multimeric structures [29,36]. Support for the contention that the larger bands are multimers of YscF is seen in Fig. 1B. Purified recombinant HT-YscF was immunoblotted with a Penta-His specific antibody (Qiagen). The results seen in Figure 1 show that the larger bands seen in panel A are also recognized by the penta-His antibody (Fig. 1B) demonstrating that the larger bands are likely recombinant proteins containing a poly-histidine tag and, therefore, contain YscF. Additionally, the purified HT-YscF was immunoblotted and probed with serum from immunized mice (Fig. 1C) to demonstrate that the immunized mice mounted an immune response against the purified HT-YscF. The larger bands seen in the Coomassie stain and visualized on the immunoblots (with both anti-Penta-His antibody and post-immune sera) could also be contaminating *E. coli* proteins, that cross-react to the penta-His antibody, this possibility cannot be currently

discounted. The presence of the higher molecular weight proteins, if they are not YscF multimers and they are from *E. coli*, likely had little influence on this study as immunization with HT-YscF induced a specific antibody response to native YscF produced by *Y. pestis* (discussed below).

#### Specificity of the antibody response to YscF

To confirm that the recombinant HT-YscF antibody response generated in immunized mice was directed against YscF from *Y. pestis*, *Y. pestis* protein extracts from the parental strain KIM8.3002 (pgm<sup>-</sup>, pla<sup>-</sup>) and extracts from a isogenic *yscF* deletion strain (kindly provided by G. Plano, University of Miami, Miami, FL.) were immunoblotted and probed with pooled antiserum from HT-YscF immunized mice (Figure 2). The results in Figure 2 demonstrate that the pooled mouse antiserum specifically recognizes YscF produced by *Y. pestis*. As seen in Figure 2, YscF is visualized on the immunoblot as a highly reactive



**Figure 2**  
Derivatives of *Yersinia pestis* KIM8-3002 (KIM5 pPCP1-minus, Sm<sup>r</sup>) were grown in a chemically defined medium at 26°C for 2 h in the presence (lanes 1, 3, and 5) or absence of calcium (lanes 2, 4, and 6). Lanes 1 and 2 contain *Y. pestis* KIM8-3002. Lanes 3 and 4 contain *Y. pestis* KIM8-3002  $\Delta$ yscF expressing YscF from pBAD18-YscF. Lanes 5 and 6 contain *Y. pestis* KIM8-3002  $\Delta$ yscF gene. After the 2 h growth, the culture was shifted to 37°C to induce expression of the Ysc type III secretion system and the Low Calcium Response. Following 4 h of growth at 37°C cultures, were centrifuged to obtain whole cell fractions and cell-free culture supernatant fractions. Total proteins from each fraction were precipitated with 10% trichloro acetic acid. Dried proteins were resuspended in SDS-PAGE sample buffer and electrophoresed in a 15% SDS-PAGE gel. Proteins were then transferred to a PVDF membrane and immuno-blotted with pooled mouse serum used at a 1:20,000 dilution. Mouse serum was obtained by bleeding mice subsequent to immunization with HT-YscF, serum from several mice was pooled to control for animal specific variation. The position and sizes for the molecular weight markers are indicated and the position of YscF is shown.

band of the correct predicted size and the YscF band is only seen only in strains containing the *yscF* gene (Figure 2, lanes 1–4). Importantly, no bands are seen in lanes 5 and 6 that contain proteins derived from the *yscF* deletion strain. In lanes 1 and 2, calcium regulation of the YscF band is seen as expected for the LCR-regulated *yscF* gene. Transcomplementaion of the  $\Delta$ yscF strain with pBAD-YscF (G. Plano, University of Miami) restored YscF reactivity to the HT-YscF serum in the  $\Delta$ yscF strain (Figure 2, lanes 3 and 4). Demonstrating that the lack of YscF reactivity in the  $\Delta$ yscF strain was due to the deletion of *yscF*. The higher molecular weight bands seen in the whole cell fraction (Figure 2, lanes 1–6) represent cross-reactive *Y. pestis* bands not specific to YscF, as they are present in the  $\Delta$ yscF samples. The same cross-reactive bands are also present in whole cell samples probed with pre-immune serum (data not shown) suggesting that the reactivity seen is not induced by immunization with HT-YscF. The higher molecular weight band seen in the culture supernatant fractions could represent a multimer of YscF (possibly a

| Table 1: IgG response to HT-YscF vaccination and LD <sub>50</sub> determination. |                |                  |                           |
|--|----------------|------------------|---------------------------|
| Immunogen  | anti-YscF GMT* | LD <sub>50</sub> | Fold increase in survival |
| PBS  | < 1:400        | 159              | -                         |
| HT-YscF  | 1:40,000       | 21,344           | 134                       |

\*Geometric mean titer for total IgG, determined from 22 HT-YscF immunized mice.

trimer) or YscF in complex with another secreted protein. This higher molecular weight species is likely related to YscF as a similar band is not seen with pre-immune sera (data not shown) or in the  $\Delta$ yscF strain (Figure 2). These results demonstrate that mice immunized with recombinant HT-YscF produce antibodies that specifically recognize YscF produced by *Y. pestis*.

### Active immunization of outbred mice followed by challenge with *Y. pestis* KIM5

To examine the ability of HT-YscF to protect mice from *Y. pestis* infection outbred mice were immunized intra peritoneally with purified HT-YscF using complete Freund's adjuvant (CFA) for primary immunization and incomplete Freund's adjuvant (IFA) for booster immunizations or with a phosphate-buffered saline (PBS, [37]) control in CFA or IFA to control for adjuvant effects. For these studies, 6-to 8-week-old female Swiss-Webster mice were immunized i.p. with 40 µg/mouse HT-YscF in PBS or PBS (control mice) alone emulsified 1:1 with CFA. Experimental mice were boosted with 40 µg/mouse HT-YscF in IFA after two weeks and with 20 µg/mouse HT-YscF in IFA at 4 weeks post-immunization. Negative control mice were boosted with PBS emulsified with IFA according to the same schedule. Two weeks following the final booster immunization, sera were collected from the HT-YscF-immunized and the PBS-immunized mice to assay for HT-YscF reactivity. Sera from 22 mice from the HT-YscF-immunized and the PBS-immunized groups were tested for total IgG reactivity. HT-YscF immunized mice had a geometric mean titer of 1:40,000 for IgG specific to HT-YscF while PBS-immunized mice had HT-YscF titers less than the lowest dilution 1:800 (Table 1). After establishing that the HT-YscF immunized mice had developed a strong antibody response to HT-YscF, the mice were challenged with *Y. pestis*. Two weeks after the final immunization, groups of 10 mice were challenged intra venously via the retro-orbital sinus with  $10^1$  to  $10^6$  CFU *Y. pestis* KIM5 (pgm<sup>-</sup>) in PBS (grown at 26°C). The mice were observed for 19 days after challenge, and the average doses required to kill 50% of the mice (LD<sub>50</sub>) for the treatment groups were calculated using the extrapolation method of Reed and Muench [38]. Mice that were immunized with HT-YscF demonstrated a 134-fold increase in the calculated LD<sub>50</sub> value as compared to PBS-immunized mice (Table 1). These results demonstrate that immunization of mice with HT-YscF was able to provide a degree of protection to the immunized mice from a subsequent challenge with *Y. pestis* (Table 1). While the protection provided by HT-YscF is not of the same magnitude as that seen with the protective antigens F1 or LcrV, the increased LD<sub>50</sub> value clearly shows that immunization with YscF affords a significant level of protection. Thus, HT-YscF becomes the only other reported antigen apart from LcrV or F1 to induce a significant protection in F1-positive *Y. pestis*. Immunization with YopD has been demonstrated to provide significant protection against a F1-minus mutant of *Y. pestis* [39]. The protection generated by HT-YscF suggests that YscF could be potentially developed as a novel subunit vaccine for *Y. pestis* or could serve as an additional antigen in a multivalent *Y. pestis* vaccine comprised of YscF, F1, and LcrV for example.

**Table 2: Antibody isotype titers from mice\* immunized with HT-YscF.**

| Antibody isotype | Titer       |
|------------------|-------------|
| Total Ig         | 1:100,000   |
| IgM              | < 1:800     |
| IgG1             | 1:100,000   |
| IgG2a            | 1:100,000   |
| IgG2b            | > 1:100,000 |
| IgG3             | 1:20,000    |
| IgA              | < 1:800     |

\*Sera from 22 mice were pooled for this analysis.

### Characterization of the antibody response to HT-YscF

Mice immunized with HT-YscF demonstrated a strong antibody response to YscF and provided protection to the vaccinated mice from lethal *Y. pestis* challenge. Due to the strong antibody response, isotyping analysis was performed to determine the predominant isotypes of antibodies produced by mice in response to vaccination with HT-YscF in CFA/IFA. Anti-YscF antibody titers were determined two weeks following the last immunization, prior to challenge. The YscF-specific antibody titers of PBS-immunized mice were below the ELISA assay baseline of 1:800 (Table 1), as was the pre-immune serum (data not shown). However, the HT-YscF immunized mice reached a GMT (geometric mean titer) of 1:40,000 (Table 1) for total IgG. Isotyping analysis was performed on the pooled sera obtained from the 22 mice selected for total the IgG analysis reported in Table 1. Pooled sera were used to minimize the animal to animal variation expected from using outbred mice. The isotyping analysis demonstrated no significant IgA or IgM production (Table 2) and a very high IgG titer (Table 2) as expected from the data in Table 1. Among the IgG subclasses IgG2b appeared to have the highest levels (Table 2), although IgG1 and IgG2a levels were also very high (Table 2). IgG3 levels were the lowest (Table 2). Generally, immunization with CFA tends to drive a strong Th1 response. Immunization with HT-YscF in CFA induced a strong Th1 response, evident by the high IgG2a response. However, a strong Th2 response is also present as seen by the high IgG1 and IgG2b levels. Immunization with HT-YscF induced a strong IgG1 response in mice and interestingly, Titball et al. have shown that high IgG1 titers to a F1/LcrV recombinant subunit vaccine correlated very well with protection against pneumonic plague in mice [40]. This suggests that YscF, which also induces a strong IgG1 response, could possibly afford some protection against pneumonic challenge as well as against systemic challenge.

### Ability of $\alpha$ -YscF to effect Yop translocation

To examine one possible method that anti-YscF could be functioning to provide protection in immunized animals the ability to translocate Yops in the presence of anti-YscF antiserum was examined. Antibody to the surface-localized LcrV has been shown to block the ability of the TTSS in *Y. pestis* to translocate Yops into cultured macrophages [41,42] but anti-LcrV was unable to block translocation into HeLa cells [21].

However, anti-LcrV was able to block Yops translocation by *Y. pseudotuberculosis* into HeLa cells [26]. Since YscF is also surface-localized the ability of anti-HT-YscF to block Yop translocation into HeLa cells was tested. Day et al have described an elegant methodology to follow the translocation of Yop effector by fusing them to a Elk reporter [43]. Elk, a eukaryotic transcriptional activator, becomes phosphorylated only after entering the nucleus, providing a reporter for translocation into eukaryotic cells [43,44]. This methodology has the advantage of not requiring cell fractionation and protease protection assays to establish the intracellular localization of translocated proteins. To test the ability of anti-YscF to block translocation *Y. pestis* KIM8-3002 was transformed with plasmid pYopE<sub>129</sub>-Elk [43]. HeLa cells were infected at an MOI of 10 and infection was allowed to progress for 4 h. After the 4 h incubation infected HeLa cells were harvested and immunoblotted to analyze YopE, Elk and PO<sub>4</sub>-Elk production. *Y. pestis* KIM8-3002 (wt; [24]) and an isogenic translocation defective strain containing a *yopD* deletion (KIM8-3002.2,  $\Delta yopD$ ; [45]) both containing pYopE<sub>129</sub>-Elk were used as positive and negative translocation controls, respectively. Immunoblots of HeLa cells infected with the wt and the  $\Delta yopD$  strains showed that only the wt strain elicited the production of PO<sub>4</sub>-Elk while the  $\Delta yopD$  strain had no production of PO<sub>4</sub>-Elk. The wt and the  $\Delta yopD$  strains were used to infect HeLa cells in the presence of a 1:10 or a 1:25 dilution of anti-YscF (titer for HT-YscF, 1:100,000) or in the presence of anti-PcrG (a *Yersinia* non-reactive antibody control, titer for PcrG, 1:20,000). The wt strain was capable of translocating YopE-Elk in presence of both anti-sera, demonstrating that anti-YscF was not capable of blocking Yops translocation and expectedly the  $\Delta yopD$  strain was still defective for translocation. The experiment likely contained sufficient antibody against YscF to block translocation. In a previous report Pettersson et al used as low as a 1:100 dilution of an anti-LcrV anti-sera with a titer of 1:20,000 for LcrV and in that experiment translocation of Yops into HeLa cells was blocked [26]. These results suggest that antibody to YscF may not exert its protective effect by blocking Yops translocation. The results also suggest that while YscF is surface-exposed in the yersinae, antibody directed against YscF, unlike, anti-LcrV cannot block translocation. This may imply that YscF activity is shielded from neutraliza-

tion by antibody, unlike LcrV activity that is blocked by antibody in some cases. However, since anti-LcrV was unable to block Yops translocation into by *Y. pestis* into HeLa cells [21] but could block translocation into cultured macrophages [41,42], the possibility remains that anti-YscF also display this type of differential blockage.


### Conclusion

In this study we have determined that immunization of mice with recombinant YscF can protect mice from an i.v. challenge with *Y. pestis*. This is the first report to our knowledge that has utilized a conserved protein from the type III secretion complex of a gram-negative pathogen as a candidate for vaccine development. This result suggests that type III secretion complexes of other gram negative pathogens could also serve as vaccine targets. YscF and its homologs are obvious targets for use as vaccine candidates as they are surface exposed and are required for virulence in all the systems examined. The protective antibody response elicited by HT-YscF is evidence that YscF is not only expressed during the course of a plague infection, but is also in a location accessible to antibodies at some point in the infectious process. The mechanism of protection by the YscF antibody response is currently under investigation. Essentially three possibilities exist to explain the antibody's protective activity: increased opsonization of the bacteria, enhanced complement binding to the bacterial surface, or direct blocking of Yops translocation into the host cells. Cytotoxicity assays (data not shown) and the ability to translocate Elk-tagged YopE into HeLa cells (Figure 3) have shown that it is unlikely that anti-YscF directly blocks Yops translocation into HeLa cells. Suggesting that a blockage of Yops translocation may not be the mechanism whereby anti-YscF antibodies are protective. The degree of protection observed after immunization with YscF is not as great as that seen for the two known protective antigens, F1 and LcrV. This result suggests that YscF could be best used in combination with the other known antigens to formulate a tri-valent vaccine for *Y. pestis*. However, further work could lead to the development of YscF as a monovalent vaccine or combined with other antigens that could be efficacious not only against *Y. pestis*, but also against *Y. enterocolitica* and *Y. pseudotuberculosis*.

### Methods

#### Cloning of *yscF* for overexpression and HT-YscF purification

Plasmid pJM119 was constructed by cloning a *Bam*HI- and *Xho*I-cleaved PCR product into pET24b (Novagen, Madison, WI). The primers used to amplify *yscF* were HT-YscF Start (5' CCG GAT CCG ATG AGT AAC TTC TCT GGA TTT 3') and HT-YscF Stop (5' CCG CTC GAG TGG GAA CTT CTG TAG GAT GCC 3'). *E. coli* BL21(DE3) (Novagen) harboring pJM119 was used for HT-YscF overexpression



**Figure 3**

*Y. pestis* strain KIM8-3002 (wt) (lane 1 and lanes 3–6) and KIM8-3002.2 ( $\Delta yopD$ ) (lane 2 and lanes 7–10) both containing plasmid pYopE<sub>129</sub>-Elk were used to infect HeLa cells at an MOI of 10. 4 h following infection the culture supernatant containing non-adherent bacteria were removed the remaining adherent HeLa cells were solubilized in 2X SDS-PAGE buffer. Following solubilization proteins were separated and immunoblotted to triplicate PVDF membranes. The triplicate blots were probed with  $\alpha$ -YopE,  $\alpha$ -Elk, or  $\alpha$ -PO<sub>4</sub>-Elk, followed by incubation with an alkaline phosphatase conjugated secondary antibody and developed using NBT/BCIP. To some samples anti-sera specific for HT-YscF (lanes 3–4 and lanes 7–8) or the *Pseudomonas* protein, PcrG (lanes 5–6 and lanes 9–10), were added at dilutions of 1:10 (lanes 3, 5, 7, and 9) or 1:25 (lanes 4, 6, 8, and 10).

according to the manufacturer's suggestions. HT-YscF was purified using Talon resin (BD Clontech, Palo Alto, CA) according to the manufacturer's directions.

#### Immunization of mice and infection with *Y. pestis* KIM5

For primary immunization 6-to 8-week-old female Swiss-Webster mice were immunized i.p. with 40  $\mu$ g/mouse His-tagged YscF or phosphate-buffered saline [37] PBS (control mice) emulsified 1:1 with complete Freund's adjuvant (CFA). Booster immunizations were performed the same as the primary immunization with the substitution of Incomplete Freund's Adjuvant for CFA. Mice were challenged with *Y. pestis* via the retro-orbital sinus using blunt-feeding needles. *Y. pestis* used to infect mice was grown overnight in HIB broth, sub-cultured to an A<sub>620</sub> of 0.2 absorbance units and grown with shaking to an A<sub>620</sub> of 1.0 absorbance unit. *Y. pestis* cells for infection were harvested by centrifugation and resuspended in PBS. Plate counts were performed to verify CFUs for the infectious doses. Infected animals were monitored for death for up to 19 days, after which survivors were euthanized by CO<sub>2</sub> inhalation, according to the guidelines of the Panel on Euthanasia of the American Veterinary Medical Association. All

animal work for this project was reviewed and approved by UND's IACUC.

#### Bacterial strains, growth and fractionation

Bacterial strains used were KIM8-3002 [24],  $\Delta yscF$  an isogenic in-frame deletion of *yscF* (G. Plano, University of Miami), and KIM8.3002.2  $\Delta yopD$  [45]. *Y. pestis* strains were grown in heart infusion broth or on tryptose blood agar base medium (Difco Laboratories, Detroit, MI) at 26°C for genetic manipulations. For physiological studies, growth of *Y. pestis* was conducted in a defined medium, TMH, as previously described [46]. Bacterial cells were fractionated as previously described [24]. Briefly, bacterial cells were chilled on ice after growth, harvested by centrifugation, and washed in cold phosphate-buffered saline (PBS; [37]). Bacterial whole cell fractions were prepared by resuspending the washed cells in cold PBS and precipitating total proteins with 10% (vol/vol) trichloroacetic acid (TCA) on ice overnight. Secreted proteins were recovered from the bacterial growth medium by centrifuging the spent medium a second time, transferring the supernatant to a clean tube, and precipitating with 10% (vol/vol) TCA on ice overnight. The TCA-pre-

cipitated proteins were pelleted by centrifugation (20,800 × g at 4°C) for 20 min and resuspended in 2X sodium dodecyl sulfate (SDS) sample buffer [37].

#### **Protein electrophoresis, visualization and immunodetection**

Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), using 12.5 % or 15 % (wt/vol) polyacrylamide gels according to the method of Laemmli [47]. Samples were boiled 3–5 min before loading on the gels. Samples were loaded such that lanes containing different culture fractions represented equivalent amounts of the original cultures. Proteins were visualized in gels using GelCode Blue stain (Pierce Chemical, Rockford, IL) according to directions. For immunoblots, proteins resolved by SDS-PAGE were transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA) using carbonate transfer buffer (pH 9.9) [48]. Specific proteins were visualized using mouse or rabbit polyclonal antibodies specific for YopE (rabbit α-YopE; gift from G. Plano, University of Miami, Miami, FL), YscF (mouse α-YscF, this study), Elk (rabbit α-Elk, Cell Signaling Technology, Beverly, MA) and PO<sub>4</sub>-Elk (rabbit α-PO<sub>4</sub>-Elk, Cell Signaling Technology). Hexahistidine tagged YscF was visualized using a penta-histidine specific antibody (mouse α-Penta-His, Qiagen, Valencia, CA) Alkaline phosphatase-conjugated secondary antibody (goat anti-rabbit immunoglobulin G or goat anti-mouse immunoglobulin G; Pierce) was used to visualize proteins by development with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (NBT-BCIP; Fisher Scientific, Fair Lawn, NJ).

#### **Antibody characterization and isotyping**

Flat-bottom, 96-well Nunc Maxisorp immunoplates (Fisher Scientific, Pittsburgh, PA) were coated with 100 μl of HT-YscF solution (4 μg/ml in Binding solution (0.1 M NaH<sub>2</sub>PO<sub>4</sub>, pH 9.0) at room temperature for 2 h (or overnight at 4°C). The wells were blocked with 200 μl/well blocking buffer (1% bovine serum albumin in TTBS (tris-buffered saline [37] + 0.5% Tween 20) and washed with TTBS. Test sera were serially diluted in blocking buffer and 100 μl of each dilution was added to duplicate wells that were incubated for 2 h at RT (or overnight at 4°C). The plates were washed and incubated for 2 h at RT with alkaline-phosphatase-conjugated anti-mouse secondary antibody. For quantitation of YscF-specific immunoglobulin isotypes and subclasses the plates were coated with alkaline-phosphatase-labeled anti-mouse isotype-specific antibody (1:400 in blocking buffer; Southern Biotech, Birmingham, AL). The wells were washed and 75 μl 3 mM para-nitro phenyl phosphate (p-NPP) was added to each well. The plates were incubated for 15 min at RT and the reaction was stopped by the addition of 50 μl of 1.5 M NaOH to each well. A<sub>405</sub> was measured to monitor the cleavage of p-NPP. Antibody titers were determined as

reciprocal numbers of the highest serum dilution that displayed values for optical density twofold higher than the value of the control serum.

#### **Infection assays**

Infection of eukaryotic cells was performed as described previously [24]. Prior to infection, eukaryotic cells were subcultured into 35-mm-diameter six-well tissue culture plates in RPMI-FBS and incubated at 37°C under 5% CO<sub>2</sub> for 48 to 72 h to a density of 5 × 10<sup>5</sup> to 8 × 10<sup>5</sup> cells per well. Cells were washed twice with warm L15 lacking FBS immediately prior to infection. Bacteria were cultivated at 26°C in HIB and used at an OD<sub>620</sub> of ~1.0 for tissue culture infections. Bacteria were added (at a multiplicity of infection (MOI) of 5 to 10) directly to prewarmed medium in the wells of the six-well plates. Plates were then centrifuged at 200 × g at RT for 5 min to achieve contact between the bacteria and the target cells and incubated at 37°C for 4 h.

#### **Translocation of YopE**

Detection of Elk-tagged YopE from pYopE<sub>129</sub>-Elk was performed as described [43]. *Y. pestis* strains carrying plasmid pYopE<sub>129</sub>-Elk were used to infect HeLa cells. After 4 h, the culture supernatants were removed, and the infected adherent cells were lysed by the addition of 100 μl of 2X SDS-PAGE lysis buffer containing Pefabloc (Roche Molecular Biochemicals, Indianapolis, IN) and phosphatase inhibitor (P-2850) cocktail (Sigma, St. Louis, MO). Samples were boiled for 5 min and loaded onto 12.5 % SDS-PAGE gels, immunoblotted to PVDF membranes and probed with Elk-1 (#9182) or phosphospecific Elk-1 (#9181) antibody preparations (Cell Signaling Technology). Anti-sera specific for HT-YscF (titer of 1:100,000, this study) or the *Pseudomonas aeruginosa* LcrG homolog, PcrG (titer of 1:20,000, Matson and Nilles, unpublished), were used at dilutions of 1:10 or 1:25 in the infection medium to assess the ability of α-YscF to effect YopE translocation.

#### **Authors' contributions**

J. S. M. cloned *yscF* for overexpression, purified HT-YscF, characterized the reactivity of antiserum to YscF, assisted with immunization and infection of mice, assisted with the LD<sub>50</sub> calculation, and wrote the draft of the manuscript. K. A. D performed immunizations and infections of the mice and performed the antibody isotyping. D. S. B. helped to design the immunization protocol and edited the manuscript. M. L. N. conceived of the study, supervised the work, calculated the LD<sub>50</sub> and edited the manuscript.

#### **Acknowledgements**

The author's would like to thank Deanna O'Bryant and Jennifer Lamoureux for assistance with mouse experiments, Jennifer Miller for help with antibody ELISAs and Gregory Plano (University of Miami, Miami, FL) for YopE antiserum and the Δ*yscF* strain of *Y. pestis*. This work was supported by the



UND Faculty Research Seed Money program. J. S. M was supported by a pre-doctoral fellowship from ND-EPSCoR. Work in M. L. N.'s laboratory is supported by NIAID grants R01-AI051520 and U01-AI54815.

## References

- Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K: **Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.** *Jama* 2000, **283**(17):2281-2290.
- Titball RW, Williamson ED: **Yersinia pestis (plague) vaccines.** *Expert Opin Biol Ther* 2004, **4**(6):965-973.
- Titball RW, Williamson ED: **Vaccination against bubonic and pneumonic plague.** *Vaccine* 2001, **19**(30):4175-4184.
- Anderson GWJ, Heath DG, Bolt CR, Welkos SL, Friedlander AM: **Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.** *Am J Trop Med Hyg* 1998, **58**(6):793-799.
- Heath DG, Anderson GWJ, Mauro JM, Welkos SL, Andrews GP, Adamovitz J, Friedlander AM: **Protection against experimental bubonic and pneumonic plague by a recombinant capsular FI-V antigen fusion protein vaccine.** *Vaccine* 1998, **16**(11-12):1131-1137.
- Davis KJ, Fritz DL, Pitt ML, Welkos SL, Worsham PL, Friedlander AM: **Pathology of experimental pneumonic plague produced by fraction I-positive and fraction I-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).** *Arch Pathol Lab Med* 1996, **120**(2):156-163.
- Drozhdov IG, Anisimov AP, Samoilova SV, Yezhov IN, Yereim SA, Karlyshev AV, Krasilnikova VM, Kravchenko VI: **Virulent non-capsulate Yersinia pestis variants constructed by insertion mutagenesis.** *J Med Microbiol* 1995, **42**(4):264-268.
- Du Y, Galyov E, Forsberg A: **Genetic analysis of virulence determinants unique to Yersinia pestis.** *Contrib Microbiol Immunol* 1995, **13**:321-324.
- Welkos SL, Davis KM, Pitt LM, Worsham PL, Freidlander AM: **Studies on the contribution of the FI capsule-associated plasmid pFra to the virulence of Yersinia pestis.** *Contrib Microbiol Immunol* 1995, **13**:299-305.
- Nakajima R, Brubaker RR: **Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.** *Infection and Immunity* 1993, **61**:23-31.
- Nakajima R, Motin VL, Brubaker RR: **Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization.** *Infection and Immunity* 1995, **63**:3021-3029.
- Nedialkov YA, Motin VL, Brubaker RR: **Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10.** *Infection and Immunity* 1997, **65**:1196-1203.
- Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: **Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression.** *J Exp Med* 2002, **196**(8):1017-1024.
- Perry RD, Straley SC, Fetherston JD, Rose DJ, Gregor J, Blattner FR: **DNA sequencing and analysis of the low-Ca<sup>2+</sup>-response plasmid pCD1 of Yersinia pestis KIM5.** *Infection and Immunity* 1998, **66**:4611-4623.
- Perry RD, Fetherston JD: **Yersinia pestis — etiologic agent of plague.** *Clinical Microbiology Reviews* 1997, **10**:35-66.
- Allaoui A, Schulte R, Cornelis GR: **Mutational analysis of the Yersinia enterocolitica virC operon: characterization of yscE, F, G, I, J, K required for Yop secretion and yscH encoding YopR.** *Mol Microbiol* 1995, **18**(2):343-355.
- Haddix PL, Straley SC: **Structure and regulation of the Yersinia pestis yscBCDEF operon.** *J Bacteriol* 1992, **174**(14):4820-4828.
- Hoiczky E, Blobel G: **Polymerization of a single protein of the pathogen Yersinia enterocolitica into needles punctures eukaryotic cells.** *Proc Natl Acad Sci U S A* 2001, **98**(8):4669-4674.
- Marenne MN, Journet L, Mota LJ, Cornelis GR: **Genetic analysis of the formation of the Ysc-Yop translocation pore in macrophages by Yersinia enterocolitica: role of LcrV, YscF and YopN.** *Microb Pathog* 2003, **35**(6):243-258.
- Cornelis GR: **The Yersinia Ysc-Yop 'type III' weaponry.** *Nat Rev Mol Cell Biol* 2002, **3**(10):742-752.
- Fields KA, Nilles ML, Cowan C, Straley SC: **Virulence role of V antigen of Yersinia pestis at the bacterial surface.** *Infection and Immunity* 1999, **67**(10):5395-5408.
- Holmström A, Olsson J, Cherepanov P, Maier E, Nordfelth R, Pettersson J, Benz R, Wolf-Watz H, Forsberg AA: **LcrV is a channel size-determining component of the Yop effector translocon of Yersinia.** *Mol Microbiol* 2001, **39**(3):620-632.
- Håkansson S, Schesser K, Persson C, Galyov EE, Rosqvist R, Homblé F, Wolf-Watz H: **The YopB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contact-dependent membrane disrupting activity.** *EMBO Journal* 1996, **15**:5812-5823.
- Nilles ML, Fields KA, Straley SC: **The V antigen of Yersinia pestis regulates Yop vectorial targeting as well as Yop secretion through effects on YopB and LcrG.** *Journal of Bacteriology* 1998, **180**(13):3410-3420.
- Nordfelth R, Wolf-Watz H: **YopB of Yersinia enterocolitica Is Essential for YopE Translocation.** *Infect Immun* 2001, **69**(5):3516-3518.
- Pettersson J, Holmström A, Hill J, Leary S, Frithz-Lindsten E, von Euler-Matell A, Carlsson E, Titball R, Forsberg A, Wolf-Watz H: **The V-antigen of Yersinia is surface-exposed before target cell contact and involved in virulence protein translocation.** *Molecular Microbiology* 1999, **32**(5):961-976.
- Sory MP, Cornelis GR: **Translocation of a hybrid YopE-adenylate cyclase from Yersinia enterocolitica into HeLa cells.** *Molecular Microbiology* 1994, **14**:583-594.
- Tardy F, Homblé F, Neyt C, Wattiez R, Cornelis GR, Ruyschaert JM, Cabaux V: **Yersinia enterocolitica type III secretion-translocation system: channel formation by secreted Yops.** *EMBO Journal* 1999, **18**(23):6793-6799.
- Blocker A, Jouhri N, Larquet E, Gounon P, Ebel F, Parsot C, Sansonetti P, Allaoui A: **Structure and composition of the Shigella flexneri "needle complex", a part of its type III secretin.** *Mol Microbiol* 2001, **39**(3):652-663.
- Kubori T, Sukhan A, Aizawa SI, Galan JE: **Molecular characterization and assembly of the needle complex of the Salmonella typhimurium type III protein secretion system.** *Proc Natl Acad Sci U S A* 2000, **97**(18):10225-10230.
- Kubori T, Matsushima Y, Nakamura D, Uralil J, Lara-Tejero M, Sukhan A, Galan JE, Aizawa SI: **Supramolecular structure of the Salmonella typhimurium type III protein secretion system.** *Science* 1998, **280**:602-605.
- Sekiya K, Ohishi M, Ogino T, Tamano K, Sasakawa C, Abe A: **Supermolecular structure of the enteropathogenic Escherichia coli type III secretion system and its direct interaction with the EspA-sheath-like structure.** *Proc Natl Acad Sci U S A* 2001, **98**(20):11638-11643.
- Wilson RK, Shaw RK, Daniell S, Knutton S, Frankel G: **Role of EscF, a putative needle complex protein, in the type III protein translocation system of enteropathogenic Escherichia coli.** *Cell Microbiol* 2001, **3**(11):753-762.
- Daniell SJ, Takahashi N, Wilson R, Friedberg D, Rosenshine I, Booy FP, Shaw RK, Knutton S, Frankel G, Aizawa S: **The filamentous type III secretion translocon of enteropathogenic Escherichia coli.** *Cell Microbiol* 2001, **3**(12):865-871.
- Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: **Current Protocols in Molecular Biology.** New York, John Wiley & Sons; 1998.
- Cordes FS, Komoriya K, Larquet E, Yang S, Egelman EH, Blocker A, Lea SM: **Helical structure of the needle of the type III secretion system of Shigella flexneri.** *J Biol Chem* 2003, **278**(19):17103-17107.
- Coligan JE, Dunn BM, Speicher DW, Wingfield PT: **Current protocols in protein science.** New York, John Wiley & Sons; 1998.
- Welkos S, O'Brien A: **Determination of median lethal and infectious doses in animal model systems.** *Methods Enzymol* 1994, **235**:29-39.
- Andrews GP, Strachan ST, Benner GE, Sample AK, Anderson GWJ, Adamovitz JJ, Welkos SL, Pullen JK, Friedlander AM: **Protective efficacy of recombinant Yersinia outer proteins against bubonic**

- plague caused by encapsulated and nonencapsulated *Yersinia pestis*. *Infect Immun* 1999, **67**(3):1533-1537.
40. Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M, Titball RV: **An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.** *Clin Exp Immunol* 1999, **116**(1):107-114.
  41. Philipovskiy AV, Cowan C, Wulff-Strobel CR, Burnett SH, Kerschen EJ, Cohen DA, Kaplan AM, Straley SC: **Antibody against V antigen prevents Yop-dependent growth of *Yersinia pestis*.** *Infect Immun* 2005, **73**(3):1532-1542.
  42. Weeks S, Hill J, Friedlander A, Welkos S: **Anti-V antigen antibody protects macrophages from *Yersinia pestis* -induced cell death and promotes phagocytosis.** *Microb Pathog* 2002, **32**(5):227-237.
  43. Day JB, Ferracci F, Plano GV: **Translocation of YopE and YopN into eukaryotic cells by *Yersinia pestis* yopN, tyeA, sycN, yscB and lcrG deletion mutants measured using a phosphorylatable peptide tag and phosphospecific antibodies.** *Mol Microbiol* 2003, **47**(3):807-823.
  44. Day JB, Lee CA: **Secretion of the orgC gene product by *Salmonella enterica* serovar Typhimurium.** *Infect Immun* 2003, **71**(11):6680-6685.
  45. Williams AW, Straley SC: **YopD of *Yersinia pestis* plays a role in the negative regulation of the low-calcium response in addition to its role in the translocation of Yops.** *Journal of Bacteriology* 1998, **180**:350-358.
  46. Straley SC, Bowmer WS: **Virulence genes regulated at the transcriptional level by Ca<sup>2+</sup> in *Yersinia pestis* include structural genes for outer membrane proteins.** *Infection and Immunity* 1986, **51**:445-454.
  47. Laemmli UK: **Cleavage of structural proteins during the assembly of the head of bacteriophage T4.** *Nature* 1970, **227**:680-685.
  48. Skrzypek E, Straley SC: **LcrG, a secreted protein involved in negative regulation of the low-calcium response in *Yersinia pestis*.** *Journal of Bacteriology* 1993, **175**:3520-3528.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

